15 results about "Integrase inhibitor" patented technology

A prophylactic or therapeutic pharmaceutical agent for HIV infectious diseases, said pharmaceutical agent being characterized by comprising a combination of: (A) a compound represented by formula (I) (wherein ring A represents a non-aromatic heterocyclic ring; ring B represents a benzene ring or a pyridine ring; Q represents —NHC(O)— or the like: each R1 independently represents a halogen atom or the like: each of R2a and R2b independently represents a hydrogen atom or the like: R3 represents an alkyl group or a haloalky 1 group: R4 represents a hydrogen atom or an alkyl group: and n represents an integer from 1 to 3) or a pharmaceutically acceptable salt thereof, and (B) a compound having an anti-HIV effect or a pharmaceutically acceptable salt thereof.

The present disclosure relates to pharmaceutical compositions (e.g., suspension formulations) including a compound of Formula I: or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable liquid vehicle. Also disclosed are methods of treating or preventing human immunodeficiency virus (HIV) in a human, including administering to the human a pharmaceutical composition disclosed herein.

The invention relates to a pyridone derivative as shown in a formula (I) or a stereoisomer thereof, a prodrug of the pyridone derivative, a pharmaceutically acceptable salt, a pharmaceutical composition containing the formula (I), and application of the pyridone derivative or the stereoisomer thereof, the prodrug of the pyridone derivative, the pharmaceutically acceptable salt and the pharmaceutical composition in preparation of a medicine for preventing and / or treating HIV (Human Immunodeficiency Virus) infection. The compound disclosed by the invention has remarkable anti-HIV virus activity, relatively low solubility and very low clearance rate, is suitable for developing a long-acting injection prevention and treatment scheme, and is used for preparing a medicine of an HIV virus integrase inhibitor or a medicine composition containing the medicine so as to benefit patients infected by HIV viruses.

A prophylactic or therapeutic pharmaceutical agent for HIV infectious diseases, said pharmaceutical agent being characterized by comprising a combination of: (A) a compound represented by formula (I) (wherein ring A represents a non-aromatic heterocyclic ring; ring B represents a benzene ring or a pyridine ring; Q represents —NHC(O)—or the like; each R1 independently represents a halogen atom or the like; each of R1a and R1b independently represents a hydrogen atom or the like, R2represents an alkyl group or a haloalkyl group, R3represents a hydrogen atom or an alkyl group; and n represents an integer from 1 to 3) or a pharmaceutically acceptable salt thereof; and (B) a compound having an anti-HIV effect or a pharmaceutically acceptable salt thereof.

The present disclosure relates generally to solid forms of the compound of Formula I: Also disclosed are pharmaceutical compositions comprising said solid forms and methods of making said solid forms. The solid forms of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

A composition comprising a stable colloid of an HIV integrase inhibitor for the preparation of an injectable, long-acting pharmaceutical product for treating and preventing HIV infection.

The present invention relates to hydroxyl-substituted fused tetracyclic heterocycle compounds, including a compound of formula (1): and pharmaceutically acceptable salts thereof, which compounds exhibit activity against HIV integrase. The present invention also relates to compositions comprising these compounds, and methods of making these compounds. The invention further relates to methods of using these compounds for treating HIV infection in a subject, including administering these compounds once-weekly for treatment of HIV infection.

Disclosed are a compound of Formula I, stereoisomers, pharmaceutically acceptable salts and deuterated compounds thereof and a method for treating, inhibiting and / or preventing a disease or disorder in a subject in need thereof: wherein A, R, G, Y and n are defined as in the present disclosure.

The invention provides an application of an anti-HIV (human immunodeficiency virus) pharmaceutical composition in immune improvement, in particular to an application of the HIV pharmaceutical composition in preparation of a medicine for immune regulation, the medicine for immune regulation is a medicine for carrying out immune regulation on HIV-1 infected people inhibited by viruses, and the anti-HIV pharmaceutical composition comprises an HIV fusion inhibitor and an HIV integrase inhibitor, the infected person is the infected person treated by an ART scheme. Experiments show that the pharmaceutical composition has a good antiviral effect and safety, and has a very good effect on immune reconstruction of patients.

The present invention relates to tetracyclic heterocyclic compounds of Formula (I): and pharmaceutically acceptable salts or prodrugs thereof, wherein R 1 as defined herein. The present invention also relates to compositions comprising at least one tetracyclic heterocyclic compound and methods of using the tetracyclic heterocyclic compounds to treat or prevent HIV infection in a subject.

The present invention pertains to: a polymorph of a pyrrolopyridine derivative which is a non-catalytic site integrase inhibitor; and a method for producing same. The novel polymorph of the present invention exhibits excellent non-hygroscopicity and stability and is thus suitable for pharmaceutical preparations.

The present disclosure relates to pharmaceutical compositions (e.g., suspension formulations) including a compound of Formula I:or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable liquid vehicle.Also disclosed are methods of treating or preventing human immunodeficiency virus (HIV) in a human, including administering to the human a pharmaceutical composition disclosed herein.